FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2591253440> ?p ?o ?g. }

• W2591253440 abstract "Abstract Abstract 1566 Background. Response-tailored management of PMLBCL is a major challenge in everyday practice, mostly due to the persistence of post-treatment residual masses of uncertain nature. PET/CT is now widely used in the definition of response and as a prognostic indicator, in Hodgkin lymphoma (HL) and diffuse large B cell lymphoma (DLBCL), while its role in patients with PMLBCL remains to be defined. Aim of the study. The IELSG-26 study was designed to prospectively evaluate the clinical role of PET/CT after rituximab and anthracycline-containing immunochemotherapy (R-CHT) in patients with PMLBCL. Methods. Between January 2007 and July 2010, 125 patients (pts) with PMLBCL were enrolled in 21 institutions and treated with R-CHOP-like (20 pts), R-VACOP-B (34 pts) or R-MACOP-B (71 pts) regimens according to the local policy; consolidation with mediastinal involved field radiotherapy (IFRT) as indicated by local guidelines was allowed. PET/CT scans were planned at baseline, at 3–4 weeks after R-CHT and at 12 weeks after radiotherapy. Central PET/CT review was performed at the end of treatment using the Deauville score (Meignan et al. Leuk Lymphoma 2009) and complete response (CR) was defined as a negative PET scan or one having minimal residual uptake lower than mediastinal blood pool (MBP) activity in regions which were FDG-PET positive at baseline according to the criteria of the International Harmonization Project in Lymphoma (Juweid et al. JCO 2007). Results. Treatment was administered as initially planned in 119 pts (including IFRT in 106); there were 6 early withdrawals (4 with early progression and 2 with stable disease receiving second-line chemotherapy). PET imaging was not done (n=2) or not evaluable due to technical problems (n=2) in 4 pts, therefore, central review of PET/CT was possible in 115/119 patients. PET/CT visual assessment at 3–4 weeks post-R-CHT showed metabolic CR in 54/115 patients (47%; 95% CI, 36%–56%): in 12 cases (10%; 95% CI, 6%–18%) PET/CT scan was completely negative (score 1 according to the Deauville criteria), while in 42 (37%; 95% CI, 28%–46%) there were small residual masses with an uptake less than MBP (score 2). PET/CT scans showed a positive residual mass after R-CHT in 61/115 pts (53%; 95% CI, 44%–62%). The residual uptake was higher than MBP but below the liver uptake (score 3) in 27 pts (23%; 95% CI, 16%–32%), slightly higher than the liver uptake (score 4) in 24 pts (21%; 95% CI, 14%–29%) and markedly higher than the liver uptake (score 5) in 10 pts (9%; 95% CI, 4%–15%). Despite only 47% of patients attaining a CR -defined by the uptake below MBP activity- after R-CHT, at a median follow-up of 2.8 years, the estimated 5-year overall survival (OS) and progression-free survival (PFS) rates were 96% (95% CI, 89%–98%) and 91% (95% CI, 84%–95%), respectively. The achievement of a CR at 3–4 weeks after R-CHT predicted a longer PFS (p=0.015) with high sensitivity but poor specificity (negative predictive value of 0.98 but positive predictive value of only 0.15) and showed a borderline impact (p=0.052) on OS. Patients with Deauville score 3 had a clinical outcome identical to that of ‘PET negative’ (score 1–2) pts and ROC analysis suggested that moving the cut-point for the definition of CR from the MBP to the liver uptake, will increase specificity while maintaining sensitivity. Indeed, defining the response using the liver uptake as a cutpoint is a better predictor for both PFS (p<0.001) and OS (p=0.001); of 10 pts with disease progression, 9 had score 4–5 and one score 2. The latter was one of the five pts with score 1–3 who were not irradiated. All the 4 recorded deaths occurred in the group of patients with score 4–5. Conclusions. Using the MBP cut-point, the PET-positive rate (Deauville score>2) after R-CHT in PMLBCL was higher (53%) than in DLBCL. However, more than 90% of pts are projected to be alive and progression-free at 5 years post treatment and a negative PET/CT after R-CHT is significantly associated with a longer PFS. Pts with score 4 and 5 had a significantly worse PFS and OS. Hence, the liver uptake may represent a more appropriate cut-point than MBP to identify poor-risk pts who may need early intensification of therapy. The frequent use of IFRT in this study precludes any clear conclusion about its role, but the new IELSG-37 randomized trial will assess whether mediastinal irradiation can be safely omitted in PMLBCL pts achieving a CR after R-CHT. Disclosures: No relevant conflicts of interest to declare." @default.
• W2591253440 created "2017-03-03" @default.
• W2591253440 creator A5000403848 @default.
• W2591253440 creator A5007119947 @default.
• W2591253440 creator A5009234092 @default.
• W2591253440 creator A5010733763 @default.
• W2591253440 creator A5015825420 @default.
• W2591253440 creator A5021191432 @default.
• W2591253440 creator A5021283633 @default.
• W2591253440 creator A5022018542 @default.
• W2591253440 creator A5024161871 @default.
• W2591253440 creator A5027811958 @default.
• W2591253440 creator A5033836018 @default.
• W2591253440 creator A5036985315 @default.
• W2591253440 creator A5045518627 @default.
• W2591253440 creator A5049017377 @default.
• W2591253440 creator A5049181862 @default.
• W2591253440 creator A5049503939 @default.
• W2591253440 creator A5056272944 @default.
• W2591253440 creator A5057411375 @default.
• W2591253440 creator A5060211572 @default.
• W2591253440 creator A5065465503 @default.
• W2591253440 creator A5069477380 @default.
• W2591253440 creator A5076114231 @default.
• W2591253440 creator A5089632360 @default.
• W2591253440 creator A5091882595 @default.
• W2591253440 date "2012-11-16" @default.
• W2591253440 modified "2023-09-28" @default.
• W2591253440 title "Role of Positron Emission Tomography (PET/CT) in Primary Mediastinal Large B Cell Lymphoma (PMLBCL): Preliminary Results of an International Phase II Trial (IELSG-26 Study) Conducted On Behalf of the International Extranodal Lymphoma Study Group (IELSG), the Fondazione Italiana Linfomi (FIL) and the UK NCRI Lymphoma Group" @default.
• W2591253440 doi "https://doi.org/10.1182/blood.v120.21.1566.1566" @default.
• W2591253440 hasPublicationYear "2012" @default.
• W2591253440 type Work @default.
• W2591253440 sameAs 2591253440 @default.
• W2591253440 citedByCount "2" @default.
• W2591253440 countsByYear W25912534402013 @default.
• W2591253440 countsByYear W25912534402014 @default.
• W2591253440 crossrefType "journal-article" @default.
• W2591253440 hasAuthorship W2591253440A5000403848 @default.
• W2591253440 hasAuthorship W2591253440A5007119947 @default.
• W2591253440 hasAuthorship W2591253440A5009234092 @default.
• W2591253440 hasAuthorship W2591253440A5010733763 @default.
• W2591253440 hasAuthorship W2591253440A5015825420 @default.
• W2591253440 hasAuthorship W2591253440A5021191432 @default.
• W2591253440 hasAuthorship W2591253440A5021283633 @default.
• W2591253440 hasAuthorship W2591253440A5022018542 @default.
• W2591253440 hasAuthorship W2591253440A5024161871 @default.
• W2591253440 hasAuthorship W2591253440A5027811958 @default.
• W2591253440 hasAuthorship W2591253440A5033836018 @default.
• W2591253440 hasAuthorship W2591253440A5036985315 @default.
• W2591253440 hasAuthorship W2591253440A5045518627 @default.
• W2591253440 hasAuthorship W2591253440A5049017377 @default.
• W2591253440 hasAuthorship W2591253440A5049181862 @default.
• W2591253440 hasAuthorship W2591253440A5049503939 @default.
• W2591253440 hasAuthorship W2591253440A5056272944 @default.
• W2591253440 hasAuthorship W2591253440A5057411375 @default.
• W2591253440 hasAuthorship W2591253440A5060211572 @default.
• W2591253440 hasAuthorship W2591253440A5065465503 @default.
• W2591253440 hasAuthorship W2591253440A5069477380 @default.
• W2591253440 hasAuthorship W2591253440A5076114231 @default.
• W2591253440 hasAuthorship W2591253440A5089632360 @default.
• W2591253440 hasAuthorship W2591253440A5091882595 @default.
• W2591253440 hasConcept C126322002 @default.
• W2591253440 hasConcept C126838900 @default.
• W2591253440 hasConcept C2775842073 @default.
• W2591253440 hasConcept C2778559949 @default.
• W2591253440 hasConcept C2779338263 @default.
• W2591253440 hasConcept C2780653079 @default.
• W2591253440 hasConcept C2989005 @default.
• W2591253440 hasConcept C509974204 @default.
• W2591253440 hasConcept C71924100 @default.
• W2591253440 hasConceptScore W2591253440C126322002 @default.
• W2591253440 hasConceptScore W2591253440C126838900 @default.
• W2591253440 hasConceptScore W2591253440C2775842073 @default.
• W2591253440 hasConceptScore W2591253440C2778559949 @default.
• W2591253440 hasConceptScore W2591253440C2779338263 @default.
• W2591253440 hasConceptScore W2591253440C2780653079 @default.
• W2591253440 hasConceptScore W2591253440C2989005 @default.
• W2591253440 hasConceptScore W2591253440C509974204 @default.
• W2591253440 hasConceptScore W2591253440C71924100 @default.
• W2591253440 hasLocation W25912534401 @default.
• W2591253440 hasOpenAccess W2591253440 @default.
• W2591253440 hasPrimaryLocation W25912534401 @default.
• W2591253440 hasRelatedWork W2279042374 @default.
• W2591253440 hasRelatedWork W2296626570 @default.
• W2591253440 hasRelatedWork W2508545986 @default.
• W2591253440 hasRelatedWork W2531597800 @default.
• W2591253440 hasRelatedWork W2550926939 @default.
• W2591253440 hasRelatedWork W2551169600 @default.
• W2591253440 hasRelatedWork W2551481738 @default.
• W2591253440 hasRelatedWork W2556236929 @default.
• W2591253440 hasRelatedWork W2558443309 @default.
• W2591253440 hasRelatedWork W2563490734 @default.
• W2591253440 hasRelatedWork W2570858546 @default.
• W2591253440 hasRelatedWork W2578565664 @default.
• W2591253440 hasRelatedWork W2580290952 @default.
• W2591253440 hasRelatedWork W2586304471 @default.
• W2591253440 hasRelatedWork W2592817296 @default.
• W2591253440 hasRelatedWork W2594524357 @default.
• W2591253440 hasRelatedWork W2784492473 @default.
• W2591253440 hasRelatedWork W2785430226 @default.

• next